HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD. Financials Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.88 CNY | -2.27% |
|
-10.14% | -17.24% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9,293 | 7,389 | 7,091 | 5,827 | - | - |
| Enterprise Value (EV) 1 | 9,293 | 7,389 | 7,091 | 5,827 | 5,827 | 5,827 |
| P/E ratio | 62.7 x | 38.2 x | 25.9 x | 15.6 x | 11.7 x | 8.91 x |
| Yield | - | 1.17% | 0.46% | 2.11% | 2.83% | 3.71% |
| Capitalization / Revenue | - | 12.2 x | 6.97 x | 4.27 x | 3.24 x | 2.5 x |
| EV / Revenue | - | 12.2 x | 6.97 x | 4.27 x | 3.24 x | 2.5 x |
| EV / EBITDA | - | 32.2 x | 18.2 x | 11.2 x | 8.52 x | 6.69 x |
| EV / FCF | - | - | -11.9 x | -43.2 x | -21.7 x | -48.6 x |
| FCF Yield | - | - | -8.43% | -2.32% | -4.62% | -2.06% |
| Price to Book | - | 2.98 x | 2.64 x | 1.95 x | 1.73 x | 1.5 x |
| Nbr of stocks (in thousands) | 108,167 | 108,167 | 108,920 | 108,143 | - | - |
| Reference price 2 | 85.91 | 68.31 | 65.10 | 53.88 | 53.88 | 53.88 |
| Announcement Date | 3/14/22 | 3/12/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 607.4 | 1,017 | 1,365 | 1,798 | 2,327 |
| EBITDA 1 | - | 229.2 | 388.8 | 519 | 683.5 | 871.5 |
| EBIT 1 | - | 188.6 | 297 | 399.2 | 531.8 | 700.8 |
| Operating Margin | - | 31.06% | 29.19% | 29.25% | 29.58% | 30.11% |
| Earnings before Tax (EBT) 1 | - | 190.9 | 295.7 | 399.5 | 532 | 701 |
| Net income 1 | 111 | 194.2 | 272 | 375.3 | 500.1 | 658.6 |
| Net margin | - | 31.97% | 26.73% | 27.49% | 27.82% | 28.3% |
| EPS 2 | 1.370 | 1.790 | 2.510 | 3.445 | 4.592 | 6.045 |
| Free Cash Flow 1 | - | - | -597.9 | -135 | -269 | -120 |
| FCF margin | - | - | -58.77% | -9.89% | -14.96% | -5.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.8000 | 0.3000 | 1.135 | 1.525 | 2.000 |
| Announcement Date | 3/14/22 | 3/12/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -598 | -135 | -269 | -120 |
| ROE (net income / shareholders' equity) | - | 8.15% | 10.6% | 12.5% | 14.8% | 16.8% |
| ROA (Net income/ Total Assets) | - | 6.63% | 8.24% | 8.62% | 10.2% | 11.6% |
| Assets 1 | - | 2,927 | 3,299 | 4,353 | 4,922 | 5,683 |
| Book Value Per Share 2 | - | 23.00 | 24.60 | 27.70 | 31.20 | 35.90 |
| Cash Flow per Share 2 | - | 2.400 | 0.8300 | 3.740 | 4.620 | 6.790 |
| Capex 1 | - | 591 | 688 | 606 | 529 | 581 |
| Capex / Sales | - | 97.3% | 67.66% | 44.4% | 29.4% | 24.97% |
| Announcement Date | 3/14/22 | 3/12/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
53.88
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.24% | 802M | |
| +16.59% | 44.44B | |
| -10.62% | 37.68B | |
| +41.76% | 39.84B | |
| +29.92% | 31.46B | |
| -9.78% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- 301096 Stock
- Financials Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
